Hematology

　Introduction

　　The Hematology Division is a part of the Division of Oncology and Hematology. Accordingly, all six staff physicians and three residents are involved in the clinical and research activities of chemotherapy for patients with both hematological and non-hematological tumors in this division. The same physicians also perform high dose chemotherapy with stem cell transplantation. The number of patients with hematological malignancies has been increasing annually. In particular, about 60 patients with malignant lymphoma are seen in this division each year.

　Routine Activities

　　We manage various kinds of hematological malignancies, including non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, acute leukemia, chronic myeloid leukemia and myelodysplastic syndrome. We also manage most patients treated with aggressive chemotherapy in the 8F ward in which we have 8 laminar air flow rooms. Our clinical practice consists of not only the treatment of patients but also consultation concerning hematological abnormalities.
　　There is a weekly case conference on Tuesday afternoon in the Division of Oncology/Hematology and a monthly joint conference on malignant lymphoma with pathologists.

　Research Activities

　　The following clinical trials were conducted this year.
Phase II Trials
1.　IDEC-C2B8 (monoclonal antibody against CD20) for low-grade non-Hodgkin's lymphoma.
2.　Cladribine for low-grade non-Hodgkin's lymphoma.
3.　JCOG-LSG 16 for lymphoblastic lymphoma or acute lymphoblastic leukemia.
4.　JCOG-LSG 22 for Hodgkin's disease.
5.　JCOG-LSG 17 for standard-risk non-Hodgkin's lymphoma.
6.　JCOG-LSG 19/20 randomized study for high-risk non-Hodgkin's lymphoma.
7.　Auto BMT for relapsed malignant lymphoma.
Phase III Trials
1.　JCOG-LSG 13/mLSG 8 for multiple myeloma.
2.　JALSG (Japan Adult Leukemia Study Group) AML 95 for acute myeloid leukemia.
3.　JCOG randomized study of autoBMT/ conventional dose chemotherapy for breast cancer.

　New Developments

　　A database of patients with malignant lymphoma was established. The database will be a useful tool for statistical analysis of malignant lymphoma.

　Statistics

Number of Patients Enrolled in Clinical Trials
　　　　Protocol No. of pts
Hodgkin's disease 　　　LSG 22 4　　
Non-Hodgkin's lymphoma 　　　LSG 16 5　　
　　　　LSG 17 34　　
　　　　LSG 19/20 18　　
Multiple myeloma 　　　LSG 13/mLSG 8 16　　
Acute myeloid leukemia 　　　JALSG AML 95 7　　
Bone marrow transplantation 　 4　　

Number of Patients Enrolled in Clinical Trials
	Protocol	No. of pts
Hodgkin's disease	LSG 22	4
Non-Hodgkin's lymphoma	LSG 16	5
	LSG 17	34
	LSG 19/20	18
Multiple myeloma	LSG 13/mLSG 8	16
Acute myeloid leukemia	JALSG AML 95	7
Bone marrow transplantation		4

(K. Ito)　

Table of Contents

	Protocol	No. of pts
Hodgkin's disease	LSG 22	4
Non-Hodgkin's lymphoma	LSG 16	5
	LSG 17	34
	LSG 19/20	18
Multiple myeloma	LSG 13/mLSG 8	16
Acute myeloid leukemia	JALSG AML 95	7
Bone marrow transplantation		4